<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>B-cell acute lymphoblastic leukemia &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/b-cell-acute-lymphoblastic-leukemia/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 12 Oct 2026 14:20:51 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>B-cell acute lymphoblastic leukemia &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Donor-Derived CD19 CAR-T Cells Deliver Lasting Remissions in Leukemia Patients After Transplant Failure</title>
		<link>https://bioengineer.org/donor-derived-cd19-car-t-cells-deliver-lasting-remissions-in-leukemia-patients-after-transplant-failure/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Mon, 12 Oct 2026 14:20:51 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[allogeneic CAR-T]]></category>
		<category><![CDATA[allogeneic hematopoietic stem cell transplantation]]></category>
		<category><![CDATA[B-cell acute lymphoblastic leukemia]]></category>
		<category><![CDATA[CAR-T therapy]]></category>
		<category><![CDATA[CD19]]></category>
		<category><![CDATA[cytokine release syndrome]]></category>
		<category><![CDATA[extramedullary disease]]></category>
		<category><![CDATA[graft-versus-host disease]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[Philadelphia chromosome]]></category>
		<category><![CDATA[relapse]]></category>
		<category><![CDATA[tyrosine kinase inhibitors]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=415843</guid>

					<description><![CDATA[A Chinese clinical study reports that donor-derived anti-CD19 CAR-T cells achieved complete remissions in 13 of 14 patients whose B-cell acute lymphoblastic leukemia relapsed after stem-cell transplantation, including most patients with extramedullary disease.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">415843</post-id>	</item>
	</channel>
</rss>
